LivaNova (LIVN) Profit After Tax Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -12.28% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 99.26% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 4.70% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 125.69% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 89.28% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -27.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 51.30% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | 106.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.81% |
| Dec 31, 2025 | -44.70% |
| Sep 30, 2025 | -18.72% |
| Jun 30, 2025 | 66.30% |
| Mar 31, 2025 | -680.40% |
| Dec 31, 2024 | 242.07% |
| Sep 30, 2024 | 550.30% |
| Jun 30, 2024 | 1,314.11% |
| Mar 31, 2024 | -669.10% |
| Dec 31, 2023 | 883.68% |
| Sep 30, 2023 | 93.18% |
| Jun 30, 2023 | -92.98% |
| Mar 31, 2023 | 146.24% |
| Dec 31, 2022 | 132.40% |
| Sep 30, 2022 | -147.09% |
| Jun 30, 2022 | 129.11% |
| Mar 31, 2022 | 109.73% |
| Dec 31, 2021 | 98.17% |
| Sep 30, 2021 | -193.26% |
| Jun 30, 2021 | 36.83% |
| Mar 31, 2021 | -182.13% |
| Dec 31, 2020 | -95.62% |
| Sep 30, 2020 | -146.12% |
| Jun 30, 2020 | -206.06% |
| Mar 31, 2020 | 352.24% |
| Dec 31, 2019 | 31.56% |
| Sep 30, 2019 | 612.00% |
| Jun 30, 2019 | -293.91% |
| Mar 31, 2019 | -183.32% |
| Dec 31, 2018 | -566.13% |
| Sep 30, 2018 | -122.54% |
| Jun 30, 2018 | -67.02% |
| Mar 31, 2018 | 58.12% |
| Dec 31, 2017 | -398.83% |
| Sep 30, 2017 | 1,873.74% |
| Jun 30, 2017 | 258.63% |
| Mar 31, 2017 | 127.91% |
| Oct 18, 2015 | -245.26% |
| Apr 24, 2015 | 0.00% |